Abstract
INTRODUCTION
Neoadjuvant chemoradiotherapy (nCRT) prior to resection of oesophageal and gastroesophageal junction cancers is considered the modern standard of care in appropriately selected patients [1] . This practice is based on a series of randomized controlled trials that have demonstrated benefits in both overall and progression-free survival with the use of nCRT for both adenocarcinoma and squamous cell carcinoma subtypes [2] [3] [4] [5] [6] [7] . Although tri-modal therapy (i.e. nCRT followed by surgical resection) has become accepted practice, the optimal time interval between neoadjuvant therapy and surgery has yet to be defined. Level 1 evidence in the literature is lacking, and as a result, there is an absence of consensus guidelines [1, 8] .
A precise duration after radiotherapy that maximizes the tumour-killing benefits of nCRT without allowing regrowth of the tumour has not been established in oesophageal adenocarcinoma. Other studies have examined this question but have relied upon predetermined time intervals determined more by convention than objective evidence. In a retrospective analysis by Ruol et al., overall survival of patients with oesophageal squamous cell carcinoma was not statistically different among those who underwent resection at less than 30 days after nCRT, between 31 and 60 days after nCRT and between 61 and 90 days after nCRT. A lower rate of local recurrence, however, was demonstrated for patients who underwent R0 resection more than 46 days after nCRT [9] . In another retrospective analysis, patients who underwent oesophageal resection for cancer before versus after 7 weeks from completion of nCRT experienced no difference in R0 resection rate, local recurrence or overall survival [10] . While these studies appear to favour longer intervals, it has also been shown that after 9 weeks, overall mortality is increased, likely due to postponing resection of active malignant disease [11] .
Overall, prior studies are conflicting and utilize arbitrary cutoffs for time interval comparison. The purpose of this study was to (i) identify a specific data-driven time interval that is associated with a change in clinical outcome and (ii) compare the clinical outcomes of patients undergoing surgical resection before and after this selected time interval.
MATERIALS AND METHODS

Patient selection
Institutional review board approval was granted prior to conducting this study. Data were collected from the National Cancer Database (NCDB), which captures data on approximately 70% of newly diagnosed cancer cases from more than 1500 cancer treatment centres in the USA and Puerto Rico. [12, 13] . Patients with more than 1 primary malignancy or with missing data with respect to timing of therapy were excluded. Patients with laryngectomy as part of their operation were also excluded as this likely represents a separate population of patients with locally advanced disease of the proximal oesophagus and/or unique tumour biology. Interval time to surgery was defined as the number of days from the completion date of nCRT to the date of surgery. Patients with intervals less than 30 days or greater than 90 days were excluded as these were likely to consist of scenarios where either neoadjuvant treatment was shortened due to intolerance or in the setting of recurrence or salvage resection, respectively.
Outcomes
The primary outcomes of this study were 30-day, 90-day and overall survival. Secondary outcomes included margin positivity, pathologic downstaging and rate of unplanned readmission within 30 days of discharge. Local recurrence rates could not be assessed due to limitations in the NCDB dataset.
Statistical analysis
Multivariable logistic regression incorporating restricted cubic splines (RCS) was used to model the relationship between time to surgery and our primary outcomes. An RCS is a function that segments a continuous variable along the x-axis and fits a separate cubic polynomial to each segment. The resulting polynomials can be joined to yield a more closely fitting regression line to better represent the distribution of data [14] . RCS functions can flexibly examine the association between a continuous variable that is a predictor and any outcome without assuming any a priori relationship [15] . The utility of RCS has been demonstrated previously in a study that evaluated the optimal timing between neoadjuvant therapy and locally advanced rectal cancer. Sun et al. were able to determine an optimal time point for surgery based on a balance between completeness of resection and tumour downstaging [16] . RCS has also been applied to other threshold determinations. Adam et al. recently published a study that, using RCS, objectively identified the number of thyroidectomies per year per surgeon that must be performed in order to minimize the incidence of complications and length of hospitalization [17] .
Using RSC, we modelled the relationship between time to surgery and our primary and secondary outcomes while adjusting for age, sex, race, Charlson/Deyo comorbidity index, treatment hospital type (academic, comprehensive community or community), insurance status, income level, education level, year of diagnosis (2006) (2007) (2008) (2009) (2010) (2011) (2012) , clinical disease stage, tumour size, tumour grade, radiation dose, extent of surgery, pathological stage, postoperative chemo, postoperative radiation, surgical margin status (positive or negative), number of lymph nodes examined and hospital length of stay. The graphic representation of RCS modelling was used to visualize an inflection point in time interval that was associated with a change in one of the most clinically relevant end-points of pathologic downstaging. This end-point also correlated with the time interval inflection point of positive distal margin.
After identification of this inflection point, we then divided our cohort into 2 groups: (i) those undergoing surgery prior to this inflection point, deemed the short-interval group and (ii) those undergoing surgery after this inflection point, deemed the longinterval group. These 2 cohorts were compared using the Wilcoxon rank-sum test for continuous variables and either Pearson's v 2 test or Fisher's exact test for categorical variables. The choice of test was predetermined: Fisher's exact test was used to compare variables containing less than 5 observations in any row, whereas Pearson's v 2 test was used to compare variables in which 5 or more observations were encountered in all rows. Multivariable logistic regression modelling was then used to analyse factors independently associated with short versus long intervals. Variables selected for multivariable adjustment were determined a priori and include those listed for RCS adjustment in the previous paragraph. A backward variable elimination method was used to produce the most parsimonious model based on the lowest Akaike information criterion.
To further evaluate our results, a sensitivity analysis was performed. Treatment group matching was performed using propensity scores. Logistic regression was used to estimate the corresponding scores from the following covariates: age, insurance status, year of diagnosis, tumour grade, pathologic T stage and pathologic N stage. Patients were matched by propensity scores using a 1:1 nearest neighbour algorithm. The resulting groups were tested with P-values and standardized differences to confirm that the groups were well matched after propensity matching. Kaplan-Meier estimates of overall survival between the short-and long-interval groups were performed on these propensity matched cohorts.
A P-value <0.05 was considered statistically significant. Statistical analysis was performed using R version 3.2.2 (R Foundation, Vienna, Austria). Overall survival was estimated using the Kaplan-Meier method. Survival between the short-and longinterval cohorts was compared using the log-rank test.
RESULTS
A total of 2444 patients were included in this study. Patients were predominantly white (97.6%) and male (89.7%) ( Table 1 ).
Additional demographic characteristics are shown in Table 1 . There were 1087 (44.5%) clinical Stage II tumours and 1357 (55.5%) clinical Stage III tumours. Most tumours (46.9%) were between 2 and 4.9 cm in size and most tumours were either poorly differentiated or undifferentiated (55.6%). The median time interval from completion of neoadjuvant therapy to surgical resection was 49 days (interquartile range 41-61 days). The distribution of these time intervals is displayed in Fig. 1 . Adjuvant chemotherapy was given to 182 patients (7.4%) and adjuvant radiation therapy was given to 9 patients (0.4%). The rate of unplanned readmission at 30 days was 6.0%. Thirty-day and 90-day all-cause mortality was 2.9% and 7.1%, respectively.
Multivariable adjusted logistic regression models utilizing RCS demonstrated a qualitative inflection point at approximately 56 days in regard to the incidence of a positive distal margin (Supplementary Material, Fig. S1 ), any positive margin (Fig. 2) , incidence of pathologic downstaging or complete pathologic response (Fig. 3) , and 30-day postoperative mortality (Fig. 4) . No inflection point was noted for 30-day unplanned readmission (Supplementary Material, Fig. S2 ). With regard to overall survival, an inflection point demonstrating increased 90-day mortality after 56 days was also noted (Fig. 4) . Division of the original cohort at this time point of 56 days yielded 2 subgroups: the short-interval group (n = 1533) that underwent surgical resection within 56 days of neoadjuvant therapy and the long-interval group (n = 911) that underwent surgical resection after 56 days. Compared with the short-interval patients, long-interval patients tended to be older (median age 62 vs 61 years, P = 0.001), less likely to have private insurance (52.7% vs 61.3%, P < 0.001), and more often below median income (29.8% vs 25.5%, P = 0.022) ( Table 2) . Clinical stage and tumour size were not statistically different between groups, however, poorly differentiated tumours comprised a greater proportion of the short-interval group (57.6% vs 52.2%, P = 0.017). Neoadjuvant radiation doses varied between groups as well, which is shown in Table 2 . The median time to surgery was 43 days (interquartile range 38-48) in the short-interval group compared to 65 days (interquartile range 59-73) in the long-interval group (P < 0.001).
Adjuvant chemotherapy was given in 9.1% of short-interval patients compared to 4.7% of long-interval patients (P < 0.001), while the incidence of adjuvant radiation therapy was not statistically different between groups. There was no difference in the incidence of positive surgical or non-surgical margin. Pathologic downstaging occurred in 50.9% of short-interval patients compared to 56.1% of long interval patients (P = 0.013). Rates of 30-day unplanned readmission and death were not statistically different between groups (Table 2) . Multivariable adjustment for clinical, tumour and treatment characteristics demonstrated a higher incidence of pathologic downstaging [odds ratio (OR) 1.38, confidence interval (CI) 1.02-1.85, P = 0.04] with a long-term interval to surgery but no difference in margin positivity (OR 0.91, CI 0.56-1.47, P = 0.69). Thirty-day rates of unplanned readmission were not statistically different between the 2 cohorts (OR 1.23, CI 0.77-1.98, P = 0.38). Although 30-day postoperative mortality was not different between groups (OR 1.56, CI 0.9-2.72, P = 0.12), the 90-day (OR 1.44, CI 1.22-1.71, P < 0.001) and overall survival (hazard ratio 1.44, CI 1.22-1.71, P < 0.001) was worse in the long-interval cohort (Table 3 ) at a median follow-up of 23 months. Overall 5-year survival is further illustrated in Supplementary Material, Fig. S3 , demonstrating lower overall survival in the long-interval cohort (32.2%) compared with the short-interval cohort (38.4%) (P < 0.001).
Propensity score matching with adjustment for clinically relevant variables yielded short-and long-interval cohorts with 911 patients per cohort. Results are summarized in Table 4 . Demographic characteristics did not differ significantly between groups. Clinical Stage III disease was more prevalent among the long-interval cohort (57.4%) as compared to the short-interval cohort (52.7%) (P = 0.043). A higher dose of radiation was also observed in the long-interval cohort (P = 0.034), however, postoperative chemotherapy was more often performed in the short-interval cohort (P = 0.003). Kaplan-Meier estimates of 5-year overall survival among 680 patients in both subgroups with available survival data remained higher in the short-interval group (41.3%) as compared to the long-interval group (31.4%) (P < 0.001) (Supplementary Material, Fig. S4 ). This result was concurrent with the survival trend previously observed by the use of RCS.
DISCUSSION
This study utilized RCS to objectively determine an optimal interval of resection of oesophageal adenocarcinoma. At an interval of 56 days between completion of neoadjuvant therapy and surgical resection for oesophageal cancer, there is an inflection point in the incidence of a positive distal margin, any positive margin, incidence of pathologic downstaging or complete pathologic response and 30-day postoperative mortality. As such, this proposed interval maximizes the benefits of nCRT while minimizing the survival disadvantage of prolonged time intervals. The Continued cohort of patients undergoing surgical resection at any time after 56 days from neoadjuvant therapy demonstrated a higher rate of pathologic downstaging and complete pathologic response consistent with the anticipated effects of neoadjuvant therapy. In contrast, worse overall survival was also experienced in this cohort, reflecting the time-sensitivity of surgical resection in the presence of malignancy, a finding confirmed with a secondary propensity score matching analysis. Thus, 56 days represent an appropriate interval for targeting surgical resection that optimizes outcomes. Neoadjuvant chemoradiation therapy has been shown to improve overall survival in patients undergoing surgical resection for oesophageal cancer [6] . While waiting a specified time interval intends for a greater effect of neoadjuvant therapy, it has been Continued unclear at which point the risk of local recurrence begins to outweigh this benefit. A recent study examined 5393 patients from the NCDB who underwent resection of oesophageal cancer following neoadjuvant therapy. Patients undergoing resection anywhere from 51 to 63 days after completion of neoadjuvant therapy were found to have a higher rate of pathologic complete response. Patients undergoing resection after at least 64 days, however, had worse overall survival [18] . Although this study parallels our conclusions, the time intervals were chosen arbitrarily and provide no greater resolution than the ranges chosen. In contrast, we utilize a novel statistical method with an objective, unbiased approach to identify an inflection point in these clinical outcomes to more accurately define a clinically relevant time point of 56 days. Additional studies have attempted to identify differences in outcomes between varying time intervals but have also determined these intervals prior to data analysis and included patients who did not receive full neoadjuvant therapy [11] . A recent study from the Netherlands also assessed differences between short and long intervals for this patient population. Although this study includes patients standardized to the CROSS trial protocol and thus removes an element of heterogeneity, the sample size is much smaller than the present study. Furthermore, Shapiro et al. use RCS to assess the non-linearity of their time interval to surgery distribution, however, this was not the primary statistical method used to identify an objective cutoff a priori, as was done in the present study [19, 20] . Smaller retrospective series have also been unable to identify differences that have become apparent in more robust analyses [9, 10] . Interestingly, the finding that longer intervals are associated with improved rates of pathologic downstaging and complete response, yet offer no advantage to overall survival, demonstrates that pathologic characteristics remain a poor surrogate for overall survival. This finding has important implications for both clinical surveillance and expectations of recurrent disease. Similar results have been observed in other studies, including those examining the optimal timing of surgery for oesophageal or rectal cancer following neoadjuvant therapy [19, 21] . Despite the advantage of using an evidence-based targeted time interval for surgical resection, several factors also contribute to the timing of surgery. In our study, a greater proportion of patients undergoing short-interval surgical resection had private insurance and incomes above the national median. This reflects the confounding disparities that are associated with a delay in surgical resection. Interestingly, the type of institution and education level of the patient did not represent a significant difference between our cohorts, suggesting that delays in surgery may be mostly financially driven. Race was not significantly different between cohorts in this study, although inferior long-term survival after surgical resection has been associated with black race in other studies [22] . Further investigation may delineate processrelated delays in care in order to arrive at our targeted interval for surgical resection. Furthermore, patients with complicated courses of neoadjuvant therapy may have inherent delays in surgical resection as a result of decreased functional status or complications directly associated with chemoradiation therapy.
As a retrospective population-based analysis, this study is limited by the generalized nature of its results and thus its applicability to patient-specific outcomes must be considered. There also exists the potential for selection bias in treatment allocation given the lack of randomization of patients, which remains a limitation of this and similar studies. Furthermore, the NCDB captures limited data with regard to demographics, performance status, and postoperative complications, any of which would otherwise further control for differences between comparison groups. Similarly, the number of institutions and surgeons represented in the NCDB by this study includes confounding differences in practice patterns that may have an unquantifiable effect on time intervals between neoadjuvant therapy and surgical resection. Certain patients may have had delay in surgical resection due to complications or malnutrition associated with their neoadjuvant therapy. Likewise, patients may have also had sooner surgical resection as a result of intolerance of neoadjuvant therapy. Thus, the interval selected at the time of consultation may have differed from the actual time interval in clinical practice. These scenarios, as well as operative approach, are not captured by the NCDB and thus cannot be accounted for in this analysis. Furthermore, while dose of radiotherapy was accounted for in our analysis, treatment regimens of chemotherapy were also not included in this data set. The current study demonstrates surgical resection for oesophageal cancer within 56 days of completion of neoadjuvant therapy is associated with increased overall survival. A randomized controlled trial design is likely necessary to fully characterize differences in outcomes between varying treatment intervals.
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